William Surbeck, MD
Rheumatology · Tulsa, OKNPI 1154382711
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $14,364 of the $17,252 with a category attached, or 83.3%. 24 manufacturers reported payments, led by Johnson & Johnson at 25.1% of the total. 2025 is the largest year on record at $4,835, 2.6 times the $1,840 reported in 2019.
Across 857 payments — averaging $20.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$4K
- Amgen$3K
- AbbVie$3K
- UCB, Inc.$2K
- GSK$809
- Genentech USA, Inc.$705
- plus $4K from 18 others
Across 25 payments — averaging $2601.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$34K
- AbbVie$31K
What the payments were for
- Consulting fees$2,28013%
- Food & beverage$14,36483%
- Education$6074%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 85 | $4,324 |
| Amgen(2 entities) | 195 | $3,446 |
| AbbVie | 171 | $2,610 |
| UCB, Inc. | 81 | $1,613 |
| GSK | 49 | $809 |
| Genentech USA, Inc. | 47 | $705 |
| Pfizer | 48 | $698 |
| Novartis | 41 | $651 |
| Lilly USA, LLC | 30 | $535 |
| AstraZeneca | 26 | $489 |
| E.r. Squibb & Sons, L.L.C. | 34 | $429 |
| Aurinia Pharma U.S., Inc. | 17 | $317 |
| Radius Health, Inc. | 5 | $96 |
| Bristol Myers Squibb | 5 | $85 |
| Fresenius Kabi USA, LLC | 4 | $81 |
| Sandoz | 4 | $78 |
| Sobi, Inc | 3 | $62 |
| Sanofi | 3 | $60 |
| Boehringer Ingelheim | 4 | $56 |
| Regeneron Healthcare Solutions, Inc. | 1 | $29 |
| Teva Pharmaceuticals USA, Inc. | 1 | $25 |
| Celltrion USA Inc. | 1 | $23 |
| Antares Pharma, Inc. | 1 | $16 |
| Scilex Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tremfya$2,532
How this compares
$17,252 in reported general payments places this provider in the 80th percentile of 67 rheumatology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 164 | $1,388,566 |
| Enbrel SureclickEtanercept | 148 | $1,256,412 |
| RinvoqUpadacitinib | 71 | $474,040 |
| Humira(Cf)Adalimumab | 28 | $273,412 |
| Xeljanz XrTofacitinib Citrate | 44 | $249,989 |
| XeljanzTofacitinib Citrate | 30 | $200,966 |
| SimponiGolimumab | 28 | $186,640 |
| Cosentyx Sensoready PenSecukinumab | 23 | $181,251 |
| EnbrelEtanercept | 22 | $167,612 |
| Cimzia (2 Pack)Certolizumab Pegol | 25 | $152,658 |
| Orencia ClickjectAbatacept | 26 | $145,953 |
| BenlystaBelimumab | 17 | $89,692 |
| ActemraTocilizumab | 13 | $62,641 |
| Actemra ActpenTocilizumab | 13 | $62,589 |
| Hydroxychloroquine Sulfate | 1,014 | $40,072 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira(Cf) | $2,610 | $747,45399 claims |
| PfizerXeljanz | $698 | $200,96630 claims |
| Johnson & JohnsonSimponi | $4,324 | $186,64028 claims |
| AmgenEnbrel | $3,446 | $167,61222 claims |
| UCB, Inc.Cimzia (2 Pack) | $1,613 | $152,65825 claims |
| GSKBenlysta | $809 | $89,69217 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $14 | $3,17950 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 67 rheumatology providers in Oklahoma.
Other rheumatology in Tulsa
- Debbie FoleyTulsa$281K
- Mary Hinojos MamutTulsa$21K
- Manuel CalvinTulsa$19K
- Alan MartinTulsa$18K
- Michael MalloyTulsa$13K
- Ellen ZanetakisTulsa$10K
- Basmah JalilTulsa$10K
- Priyatha GarlapatiTulsa$8K
- James McKayTulsa$5K
- Lindsay CunninghamTulsa$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.